Global Brain has invested in Veritas In Silico Inc. (VIS), a biotech company focusing on small molecule drug discovery targeting mRNA, through its KDDI Open Innovation Fund III (KOIF III) and GB-VII Growth Fund Investment Limited Partnership (GB-VII).

VIS has developed their ibVIS platform that combines informatics and experimental biology to discover small molecule drugs (SMDs) targeting motifs on the mRNA. The ibVIS platform can be applied to discovery of not only SMDs but also antisense oligonucleotides (ASOs). VIS can meet a wide range of drug discovery needs for pharmaceutical companies by using ASOs for rare diseases and SMDs for chronic diseases and infectious diseases. VIS’s mission is to build a society where every patient, especially those with diseases that currently have no satisfactory treatment, can look forward to a brighter future through the realization of mRNA-targeted drugs.

Global Brain decided to invest in VIS, thinking highly of their unique platform technology and strong management team. Through this investment, Global Brain will proactively leverage its resources to support VIS’s further growth both in Japan and overseas.

About VIS

Location
Shinagawa-ku, Tokyo, Japan
Representative
Shingo Nakamura
Founded
November 2016
URL
https://www.veritasinsilico.com/

About KOIF III

Name
KDDI Open Innovation Fund III
General Partner
Global Brain Corporation
Fund Size
20 Billion JPY

About GB-VII

Name
GB-VII Growth Fund Investment Limited Partnership
General Partner
Global Brain Corporation

About Global Brain

Location
Tokyo, Japan
Representative
Yasuhiko Yurimoto
Founded
January 1998
URL
https://globalbrains.com/